Document is current
Any future updates will be listed below
-
Authors
Lai, Rocky
Kurtz, Sherry L.
Gould, Victoria
Tran, Anthony
Afkhami, Sam
Brosch, Roland
Lindestam Arlehamn, Cecilia S.
Xing, Zhou
Elkins, Karen L.
Behar, Samuel M.
-
Funding
Funding for this research was provided by:
Agence Nationale pour la Recherche (ANR-10-LABX62-IBEID)
TBVAC-HORIZON project (101080309)
The Canadian Institutes for Health Research (CIHR) Foundation Program
National Institute of Allergy and Infectious Diseases (5P01AI181898)
National Institute of Allergy and Infectious Diseases (5P01AI181898)
- License Information
-
More Information
Article History
Received: 3 March 2026
Accepted: 27 May 2026
First Online: 5 June 2026
Competing interests
: S.A. and Z.X. are inventors on a published PCT patent application no. PCT/CA2023/051523 entitled “Trivalent tuberculosis vaccine,” which describes the ChAd.TB vaccine used in the studies described herein. The other authors do not have a competing interest.
